| Literature DB >> 28395140 |
Chunrong Qu1, Mingmin Ding1, Yingmin Zhu2, Yungang Lu2, Juan Du3, Melissa Miller4, Jinbin Tian2, Jinmei Zhu1, Jian Xu5,6, Meng Wen1, Aga Er-Bu7, Jule Wang7, Yuling Xiao1, Meng Wu4, Owen B McManus4, Min Li4, Jilin Wu6,8, Huai-Rong Luo9, Zhengyu Cao5, Bing Shen3, Hongbo Wang10, Michael X Zhu2,6, Xuechuan Hong1,7.
Abstract
Transient receptor potential canonical 3/6/7 (TRPC3/6/7) are highly homologous receptor-operated nonselective cation channels. Despite their physiological significance, very few selective and potent agonists are available for functional examination of these channels. Using a cell-based high throughput screening approach, a lead compound with the pyrazolopyrimidine skeleton was identified as a TRPC6 agonist. Synthetic schemes for the lead and its analogues were established, and structural-activity relationship studies were carried out. A series of potent and direct agonists of TRPC3/6/7 channels were identified, and among them, 4m-4p have a potency order of TRPC3 > C7 > C6, with 4n being the most potent with an EC50 of <20 nM on TRPC3. Importantly, these compounds exhibited no stimulatory activity on related TRP channels. The potent and selective compounds described here should be suitable for evaluation of the roles of TRPC channels in the physiology and pathogenesis of diseases, including glomerulosclerosis and cancer.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28395140 PMCID: PMC5720685 DOI: 10.1021/acs.jmedchem.7b00304
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446